1887

Abstract

Subunit approaches to vaccines against viral diseases have resulted in the development of a number of methods for presentation of defined epitopes to the immune system. We have exploited a highly immunogenic presentation system based on hepatitis B core antigen (HBcAg) particles to produce a number of candidate vaccines against simian immunodeficiency virus (SIV). Recombinant particles have been produced in bacteria which carry multiple copies of defined or predicted neutralizing epitopes of SIV at a number of different sites within the particle. In parallel, a number of synthetic peptide-based SIV vaccines have been produced based on homology to reported neutralizing epitopes in human immunodeficiency virus. Although potent immune responses were elicited against both particulate and peptide forms of the antigen, neutralizing antibodies were not induced as judged by available assays.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-73-10-2569
1992-10-01
2024-03-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/73/10/JV0730102569.html?itemId=/content/journal/jgv/10.1099/0022-1317-73-10-2569&mimeType=html&fmt=ahah

References

  1. Adams S. E., Dawson K. M., Gull K., Kingsman S. M., Kingsman A. J. 1987; The expression of hybrid HIV:Ty virus-like particles in yeast. Nature, London 329:68–70
    [Google Scholar]
  2. Berzofsky J. A. 1991; Approaches and issues in the development of vaccines against HIV. Journal of Acquired Immune Deficiency Syndromes 4:451–459
    [Google Scholar]
  3. Bjorling E., Broliden K., Bernardi D., Utter G., Thorstennson R., Chiodi F., Norrby E. 1991; Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proceedings of the National Academy of Sciences, U.S.A. 88:6082–6086
    [Google Scholar]
  4. Brown A. L., Francis M. J., Hastings G. Z., Parry N. R., Barnett P. V., Rowlands D. J., Clarke B. E. 1991; Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. Vaccine 9:595–601
    [Google Scholar]
  5. Burke K. L., Dunn G., Ferguson M., Minor P. D., Almond J. W. 1988; Antigen chimeras of poliovirus as potential new vaccines. Nature, London 332:81–82
    [Google Scholar]
  6. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. 1986; Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO Journal 5:3065–3071
    [Google Scholar]
  7. Clarke B. E., Newton S. E., Carroll A. R., Francis M. J., Appleyard G., Syred A. D., Highfield P., Rowlands D. J., Brown F. 1987; Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature, London 330:381–384
    [Google Scholar]
  8. Clarke B. E., Brown A. L., Grace K. G., Hastings G. Z., Brown F., Rowlands D. J., Francis M. J. 1990; Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria. Journal of General Virology 71:1109–1117
    [Google Scholar]
  9. Clarke B. E., Carroll A. R., Brown A. L., Yon J., Parry N. R., Rud E. W., Francis M. J., Rowlands D. J. 1991; Expression and immunological analysis of hepatitis B core fusion particles carrying internal heterologous sequences. In Vaccines 91 pp. 313–318 Edited by Chanock R. M., Ginsberg H. S., Brown F., Lemer R. A. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  10. Gardner M. 1991; SIV vaccines: current status. Vaccine9787–791
    [Google Scholar]
  11. Gnann J. W. Jr, Schwimmbeck P. L., Nelson J. A., Truax A. B., Oldstone M. B. A. 1987; Diagnosis of AIDS by using a 12 amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. Journal of Infectious Diseases 156:261–267
    [Google Scholar]
  12. Golding H., Shearer G. M., Hillman K., Lucas P., Manische J., Zajak R. A., Clerici M., Gress R. E., Boswell R. N., Golding B. 1989; Common epitope in human immunodeficiency virus (HIV-1) gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV-1-infected individuals. Journal of Clinical Investigation 83:1330–1435
    [Google Scholar]
  13. Goudsmit J., Debouck C., Meloen R. H., Smit L., Barker M., Asher D. M., Wolff A. V., Gibbs C. J., Gajdusek D. C. 1988; Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proceedings of the National Academy of Sciences, U.S.A. 85:4478–4482
    [Google Scholar]
  14. Houghten R. A. 1985; General method for the rapid solid phase synthesis of large numbers of peptides – specificity of antigen-antibody interaction at the level of individual amino acids. Proceedings of the National Academy of Sciences, U.S.A. 82:5131–5135
    [Google Scholar]
  15. Kent K. A., Gritz L., Stallard G., Cranage M. P., Colignon C., Thiriart C., Corcoran T., Silvera P., Stott E. J. 1991; Production and characterisation of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS 5:829–836
    [Google Scholar]
  16. Kent K. A., Rud E., Corcoran T., Powell C., Thiriart C., Colignon C., Stott E. J. 1992; Identification of two neutralising and eight non-neutralising epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Research and Human Retroviruses 8:737–741
    [Google Scholar]
  17. Kniskern P. J., Hagoplan A., Montgomery D. L., Burke P., Dunn N. R., Hoffman K. J., Miller W. J., Ellis R. W. 1986; Unusually high-level expression of a foreign gene (hepatitis B core antigen) in Saccharomyces cerevisiae . Gene 46:135–141
    [Google Scholar]
  18. Lanford R. E., Kennedy R. C., Dreesman G. R., Eichberg J. W., Notvall L., Luckow V. A., Summers M. D. 1989; Expression of hepatitis B surface and core antigens using a baculovirus expression vector. In Viral Hepatitis and Liver Disease pp. 372–378 Edited by Zuckerman A. J. New York: Alan R. Liss;
    [Google Scholar]
  19. Liu F., Zinnecker M., Hamaoka T., Katz D. H. 1979; New procedures for coupling proteins to a synthetic copolymer of D-glutamic acid and D-lysine and isolation of such conjugates. Journal of Immunological Methods 82:91–100
    [Google Scholar]
  20. Matsuda K., Satoh S., Ohori H. 1988; DNA-binding activity of hepatitis B e antigen polypeptide lacking the protamine-like sequence of nucleocapsid protein of human hepatitis B virus. Journal of Virology 62:3517–3521
    [Google Scholar]
  21. Milich D. R., McLachlan A. 1986; The nucleocapsid of the hepatitis B virus is both a T cell-independent and a T cell-dependent antigen. Science 234:1398–1401
    [Google Scholar]
  22. Miller C., Gardner M. B. 1991; AIDS and mucosal immunity: usefulness of the SIV macaque model of genital mucosal transmission. Journal of Acquired Immune Deficiency Syndromes 4:1169–1172
    [Google Scholar]
  23. Pasek M., Goto T., Gilbert W., Zink B., Schaller H., MacKay P., Leadbetter G., Murray K. 1979; Hepatitis B virus genes and their expression in E. coli . Nature, London 282:575–579
    [Google Scholar]
  24. Robinson W. E. Jr, Montefiori D. C., Mitchell W. M., Prince A. M., Alter H. J., Dreesman G. R., Eichberg J. W. 1989; Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proceedings of the National Academy of Sciences, U.S.A. 86:3185–3189
    [Google Scholar]
  25. Rowlands D. J. 1990; Problems and prospects for synthetic peptide vaccines. In Control of Virus Diseases pp 123–141 Society for General Microbiology Symposium 45. Edited by Dimmock N. J., Griffiths P. D., Madely C. R. Cambridge: Cambridge University Press;
    [Google Scholar]
  26. Rud E. W., Yon J. R., Larder B. A., Clarke B. E., Cooke N., Cranage M. P. 1992; Infectious molecular clones of SIVmac32H: nef deletion controls ability to reisolate virus from rhesus macaques. In Vaccines 92. Modem Approaches to New Vaccines Including Prevention of AIDS pp. 229–235 Edited by Brown F., Chanock R. M., Ginsberg H. S., Lemer R. A. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  27. Schodel F., Moriarty A. M., Peterson D. L., Zheng J., Hughes J. L., Will H., Leturcq D. J., McGee J. S., Milich D. R. 1992; The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. Journal of Virology 66:106–114
    [Google Scholar]
  28. Shafferman A., Jahrling P. B., Benveniste R. E., Lewis M. G., Phipps T. J., Eden-McCutchan F., Sadoff J., Eddy G. A., Burke D. S. 1991; Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proceedings of the National Academy of Sciences, U.S.A. 88:7126–7130
    [Google Scholar]
  29. Stahl S., Murray K. 1989; Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proceedings of the National Academy of Sciences, U.S.A. 86:6283–6287
    [Google Scholar]
  30. Towbin H., Staehelin T., Gordon J. 1979; Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, U.S.A. 76:4350–4354
    [Google Scholar]
  31. Valenzuela P., Coit D., Medina-Selby A., Kuo C. H., Van Nest G., Burke R. L., Urdea M. S., Graves P. V. 1985; Antigen engineering in yeast: synthesis and assembly of hybrid hepatitis B surface antigen-herpes simplex 1 gD particles. Bio/Technology 3:323–326
    [Google Scholar]
  32. Voller A., Bartlett A., Bidwell D. E., Clark M. F., Adams A. N. 1976; Detection of viruses by enzyme-linked immunosorbent assay (ELISA). Journal of General Virology 33:165–167
    [Google Scholar]
  33. Wigzell H. 1991; Prospects for an HIV-vaccine. FASEB Journal 5:2406–2411
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-73-10-2569
Loading
/content/journal/jgv/10.1099/0022-1317-73-10-2569
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error